Evidence map›Paper›PMID 39980767›Full record

ArticleEuropean heart journal supplements : journal of the European Society of Cardiology2025

Acute myocarditis: 2024 state of the art.

Enrico Ammirati, Iside Cartella, Marisa Varrenti, Adelina Selimi, Paola Sormani, Andrea Garascia, Matteo Palazzini

Abstract read
In one paragraph

Article in European heart journal supplements : journal of the European Society of Cardiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Incidence and predictors of major arrhythmic events after myocarditis: a systematic review and meta-analysis.Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology · 2026
    Pooled it
  2. Post-viral myocarditis.Heart failure reviews · 2026
    Review
  3. Observational
  4. Review
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Observational
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Enrico AmmiratiDe Gasperis Cardio Center, Niguarda Hospital, Piazza Ospedale Maggiore 3, 20162 Milan, Italy.ORCID https://orcid.org/0000-0002-1676-5257
Iside CartellaDe Gasperis Cardio Center, Niguarda Hospital, Piazza Ospedale Maggiore 3, 20162 Milan, Italy.
Marisa VarrentiDe Gasperis Cardio Center, Niguarda Hospital, Piazza Ospedale Maggiore 3, 20162 Milan, Italy.
Adelina SelimiCardiology and Arrhythmology Clinic, University Hospital 'Umberto I-Lancisi-Salesi', Ancona, Italy.ORCID https://orcid.org/0000-0002-6080-8031
Paola SormaniDe Gasperis Cardio Center, Niguarda Hospital, Piazza Ospedale Maggiore 3, 20162 Milan, Italy.
Andrea GarasciaDe Gasperis Cardio Center, Niguarda Hospital, Piazza Ospedale Maggiore 3, 20162 Milan, Italy.
Matteo PalazziniDe Gasperis Cardio Center, Niguarda Hospital, Piazza Ospedale Maggiore 3, 20162 Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute myocarditis (AM) is an inflammatory injury of the myocardium secondary to infections, systemic autoimmune disorders, medications, or toxic agents. The patient's genetic underground is a likely concurrent aetiology/contributory mechanism recently implicated in a proportion of AM. This review focuses on some critical new concepts of AM, updated indications for endomyocardial biopsy when cardiac magnetic resonance imaging is not sufficient or feasible, and estimation of long-term events after discharge. Furthermore, studies exploring AM as the cause of sudden cardiac death will be examined to assess the characteristics of patients who die due to AM before hospital admission. Managing the most severe clinical presentation, termed fulminant myocarditis (FM) characterized by haemodynamic instability due to ventricular arrhythmias or severe acute pump failure, will be summarized. Specific issues aimed to reduce the high mortality rate of FM, like early recognition, referring these patients from spoke centres to a hub centre, timely temporary mechanical circulatory support when indicated, early endomyocardial biopsy, and eventually immunosuppression, will be briefly discussed. Immune checkpoint inhibitors and desmosomal gene variant-associated AM will be highlighted as paradigmatic new forms of myocarditis.

Indexed as

Endomyocardial biopsyImmune checkpoint inhibitorsMyocarditisTherapy

Identifiers

PMID39980767
PMCPMC11836720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.